CRNX
insider transactionsCrinetics Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-6.9K
0 buy · 6.9K sell
Net value · 30d
-$246.1K
$0 in · $246.1K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
2
0 buy · 6.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$22.0K
608 sh · $36.22
Own -9%
-
Sell·S
Director · 10b5-1
$224.1K
6.3K sh · $35.62
Own -47%
-
Other·G
President & CEO
$0
111.1K sh
Own -18%
-
Other·G
President & CEO
$0
80.0K sh
Own -37%
-
Other·G
President & CEO
$0
222.2K sh
Own -34%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Stephanie Okey 10b5-1 | Sell S | 608 | $22.0K |
| Jun 17, 2026 | Stephanie Okey 10b5-1 | Sell S | 6.3K | $224.1K |
| May 29, 2026 | Richard Scott Struthers KEY | Other G | 111.1K | $0 |
| May 29, 2026 | Richard Scott Struthers KEY | Other G | 80.0K | $0 |
| May 29, 2026 | Richard Scott Struthers KEY | Other G | 222.2K | $0 |
About CRNX insider trading
This page tracks insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.